Article Sidebar

Submitted
March 13, 2025
Accepted
May 10, 2025
Published
June 30, 2025
Download
PDF
Statistic
Read Counter : 275

Main Article Content

Abstract

Interleukin-17A (IL-17A) plays a pivotal role in the pathogenesis of psoriatic arthritis. We generated a high-affinity monoclonal antibody against IL-17A using hybridoma technology and characterized its binding kinetics, neutralization potency, and in vivo efficacy in an experimental arthritis model. The antibody demonstrated superior affinity compared to existing therapeutics and significantly reduced disease severity in treated animals. These results support the potential of this novel antibody as a therapeutic candidate. 

Keywords

Cytokine Inhibition IL-17A Inflammation Monoclonal Antibody Psoriatic Arthritis Therapeutic Antibodies

Article Details

License

Copyright (c) 2025 Widad Abd Aljabbar Mozzan, Nada Khazal K. Hindi, Ashwaq M. S. Al-Jbouri, Yasmeen Ali Hussein, Hayder Al-Aubaidy (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Mozzan, W.A.A.J. (2025) “Generation and Characterization of a Novel Anti-IL-17A Monoclonal Antibody for the Treatment of Psoriatic Arthritis”, Trends in Pharmaceutical Biotechnology, 3(1), pp. 49–63. doi:10.57238/tpb.2025.153196.1027.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

How to Cite

Mozzan, W.A.A.J. (2025) “Generation and Characterization of a Novel Anti-IL-17A Monoclonal Antibody for the Treatment of Psoriatic Arthritis”, Trends in Pharmaceutical Biotechnology, 3(1), pp. 49–63. doi:10.57238/tpb.2025.153196.1027.

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.